Expert Interview
Discussing the FDA Approval of Medtronic’s OmniaSecure™ Defibrillation Lead for Conduction System Pacing
Ticker(s): MDT, BSX, ABTInstitution: Mayo Clinic
- Cardiac electrophysiologist specializing in arrhythmia management, including atrial fibrillation, ventricular tachycardia, inherited arrhythmia syndromes, and sudden cardiac arrest.
- Treats a high volume of patients annually requiring electrophysiology procedures, including catheter ablation, pacemaker implantation, and cardiac resynchronization therapy.
- Primary research and clinical focus is on advanced ablation techniques, inherited arrhythmias, novel pacing modalities (including leadless and conduction system pacing), and management of arrhythmias in specialized populations such as athletes.
How are you currently approaching device selection and lead strategy in patients requiring pacing and/or defibrillation, and what factors influence your use of conduction system pacing?
Added By: sara_adminHow do you anticipate this technology impacting procedural approaches, including implantation techniques, workflow, and operator training?
Added By: sara_adminIn which patient populations do you see the greatest potential benefit from combining defibrillation capability with conduction system pacing?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
